Pharmacotherapeutic potential of daidzein: insights into mechanisms and clinical relevance

Abstract

Daidzein, a soy-derived isoflavone, has gained significant attention due to its diverse pharmacological properties, including antioxidant, anti-inflammatory, and estrogenic activities. This review synthesizes current research on daidzein's biological effects, focusing on its role in chronic diseases, such as cancer, osteoporosis, cardiovascular disorders, and neurodegenerative conditions. Mechanistically, daidzein exerts its effects through estrogen receptor modulation, activation of antioxidant pathways, and regulation of inflammatory mediators. Studies have demonstrated its potential in inhibiting cancer cell proliferation, improving bone mineral density, and reducing oxidative stress in cardiovascular diseases. Furthermore, daidzein's neuroprotective effects suggest promise in managing neurodegenerative disorders like Alzheimer's and Parkinson's disease. Despite its therapeutic potential, the bioavailability and metabolism of daidzein remain critical challenges, with interindividual variability influencing its efficacy. Advances in nanotechnology and formulation strategies aim to enhance its bioavailability and therapeutic applications. This review underscores the need for well-designed clinical trials to validate daidzein's efficacy and safety across different populations. Future research should also explore synergistic effects with other bioactive compounds to maximize its clinical utility.

Keywords: Antioxidant; Bioavailability; Chronic diseases; Daidzein; Estrogenic activity; Isoflavone.